Another recent report described the successful treatment of a case of refractory, KMT2A-rearranged infant MPAL using a combination of immunotherapy agents targeting CD19 (blinatumomab) and CD33 (gemtuzumab) [137]. This evidence concerns the gene CD19 and mixed phenotype acute leukemia.